Campaign Promises

Cabinet/Departments -> Health & Human Services -> Cancer/Cancer Research

ItemHealth & Human Services
Cancer/Cancer ResearchGrade
The Promise: "Will double federal funding for cancer research within 5 years."
When/Where: Obama-Biden Plan to Combat Cancer, 09/06/08.
Status:For FY2009, funding for cancer research was appropriated in the amount of $37.911B (the amount to "double"), broken down as follows:
- National Institutes of Health (NIH): $30.317B
- National Cancer Institute (NCI): $4.964B
- Food & Drug Administration (FDA): $2.040B
- Centers for Desease Control (CDC): $340M
- Department of Defense (DoD): $250M

The amount appropriated for FY2010 was NIH ($31.010), NCI ($5,103B), FDA ($2.362B), CDC ($475M) and DoD ($249M) for a total of $39.199B.

Under FY2011 Continuing Resolution, the appropriations were the same as for FY2010 except that DoD funding was eliminated, bring the total down to $38.950B.

FY2012 funding was in the following amounts: NIH ($35.000B), NCI ($5.740), FDA ($2.875), and CDC ($641M) for a total of $44.238B.

Although cancer research received small increases as reflected above, it was inconceivable that the $75.822B goal (double the FY2009 level) could be attained by FY2014.

This promise was not fulfilled.
The Promise: "...will immediately direct his Secretary of Health and Human comprehensively examine the various cancer-related efforts of federal agencies, and provide recommendations to eliminate barriers to effective coordination across federal agencies and between the federal government and other stakeholders."
When/Where: The Obama-Biden Plan to Combat Cancer, dated 09/06/08.
Status:On 03/10/14, Health & Human Services (HHS) released its FY2014-FY2018 Strategic Plan to the public. The plan has the following goals:
Strategic Goal 1: Strengthen Health Care
Strategic Goal 2: Advance Scientific Knowledge and Innovation
Strategic Goal 3: Advance the Health, Safety, and Well-Being of the American People
Strategic Goal 4: Ensure Efficiency, Transparency, Accountability, and Effectiveness of HHS Programs

Somewhere in this plan, the thrust of this promise could have been addressed.

As of end-CY2016, President Obama is not known to have taken the promised action, "immediately" or otherwise.

This promise was not fulfilled.
The Promise: "Will provide the CDC $50 million in new funding to determine the most effective approaches that assist not only navigation of cancer patients through diagnosis and treatment processes, but also provide easy-to-understand information on the necessary follow-up steps to ensure continued lifelong health."
When/Where: The Obama-Biden Plan to Combat Cancer, dated 09/06/08.
Status:The Centers for Disease Control (CDC) FY2009 budget for cancer prevention and control was $340M.

During subsequent years, cancer prevention and control was funded as follows:

FY2010....$370M (+$30M)
FY2011....$325M (-$45M)
FY2012....$371M (+$46M)
FY2013....$337M (-$34M)
FY2014....$350M (+$13M)
FY2015....$352M (+$2M)
FY2016....$356M (+$4M)
FY2017....$302M (-$54M Requested)

Over President Obama's two terms in office, no "new funding" amounting to $50M was provided to the CDC for cancer prevention and control.

This promise was not fulfilled.
The Promise: "...will seek to increase participation in clinical trials to 10 percent of adult cancer patients by requiring coverage of patient clinical trial costs in the new public and private plans offered through the National Health Insurance Exchange..."
When/Where: Obama-Biden Plan to Combat Cancer, 09/06/08.
Status:According to a Lancet Oncology Journal study published in 02/06, two of the main barriers to patient participation in clinical trials are (1) concern that joining a trial might reduce the patient's quality of life and (2) that the patient might receive a placebo instead of real medication to combat the cancer the patient is experiencing.

The National Cancer Institute estimated in 07/09 that less than 5% of adults diagnosed with cancer each year would participate in clinical trials.

A CY2016 report issued by the American Society of Clinical Oncology (ASCO) states the following: "...assembling and analyzing data from millions of electronic health records...will allow us to learn from every individual treated for cancer - not just the fewer than 5% of patients who currently participate in clinical trials."

This promise was not fulfilled.